Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers

Preclinical studies have demonstrated synergy between poly(ADP-ribose) polymerase (PARP) and phosphatidylinositol-3-kinase (PI3K)/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Discov
Главные авторы: Yap, Timothy A., Kristeleit, Rebecca, Michalarea, Vasiliki, Pettitt, Stephen J., Lim, Joline S.J., Carreira, Suzanne, Roda, Desamparados, Miller, Rowan, Riisnaes, Ruth, Miranda, Susana, Figueiredo, Ines, Rodrigues, Daniel Nava, Ward, Sarah, Matthews, Ruth, Parmar, Mona, Turner, Alison, Tunariu, Nina, Chopra, Neha, Gevensleben, Heidrun, Turner, Nicholas C., Ruddle, Ruth, Raynaud, Florence I., Decordova, Shaun, Swales, Karen E., Finneran, Laura, Hall, Emma, Rugman, Paul, Lindemann, Justin P.O., Foxley, Andrew, Lord, Christopher J., Banerji, Udai, Plummer, Ruth, Basu, Bristi, Lopez, Juanita S., Drew, Yvette, de Bono, Johann S.
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611385/
https://ncbi.nlm.nih.gov/pubmed/32532747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-0163
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы